YS vs. AVIR, QTTB, KMDA, XOMA, EPIX, EBS, INZY, VNDA, RVNC, and CRMD
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include Atea Pharmaceuticals (AVIR), Q32 Bio (QTTB), Kamada (KMDA), XOMA (XOMA), ESSA Pharma (EPIX), Emergent BioSolutions (EBS), Inozyme Pharma (INZY), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), and CorMedix (CRMD). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.
YS Biopharma currently has a consensus target price of $5.25, indicating a potential upside of 528.74%. Given YS Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe YS Biopharma is more favorable than Atea Pharmaceuticals.
Atea Pharmaceuticals received 16 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
YS Biopharma has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.
In the previous week, YS Biopharma had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for YS Biopharma and 2 mentions for Atea Pharmaceuticals. YS Biopharma's average media sentiment score of 1.42 beat Atea Pharmaceuticals' score of 0.94 indicating that YS Biopharma is being referred to more favorably in the media.
YS Biopharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.
52.6% of YS Biopharma shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
YS Biopharma has higher revenue and earnings than Atea Pharmaceuticals.
Summary
YS Biopharma beats Atea Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
